Following the receipt of this license, Azilect (rasagiline), a product co-developed between Teva and Lundbeck, and a joint development of Teva and the Technion Israel institute of Technology, will be launched in Israel in March 2005.
“We are extremely pleased to have received the first approval for the marketing of Azilect here in Israel where the product originated and was developed,” said Israel Makov, president and CEO of Teva. “With additional approvals anticipated in other countries during 2005, Azilect should become an important treatment option for patients suffering from Parkinson’s disease.”
Azilect is a novel, potent, second-generation, selective, irreversible monoamine oxidase type-B (MAO-B) inhibitor that blocks the breakdown of dopamine, a substance in the brain needed to facilitate movement.